PNTG logo

The Pennant Group, Inc. Stock Price

NasdaqGS:PNTG Community·US$1.1b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 14 Fair Values set on narratives written by author

PNTG Share Price Performance

US$35.73
7.56 (26.84%)
US$38.17
Fair Value
US$35.73
7.56 (26.84%)
6.4% undervalued intrinsic discount
US$38.17
Fair Value
Price US$35.73
AnalystConsensusTarget US$38.17
AnalystLowTarget US$36.00
AnalystHighTarget US$40.00

PNTG Community Narratives

·
Fair Value US$38.17 6.4% undervalued intrinsic discount

Aging US Demographics Will Expand Home Health Services

0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
·
Fair Value US$36 0.8% undervalued intrinsic discount

Medicare Cuts, Workforce Strain Will Test Operations But Spark Resilience

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
·
Fair Value US$40 10.7% undervalued intrinsic discount

Aging Population And Home Care Will Expand Market Access

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
US$36
0.8% undervalued intrinsic discount
Revenue
10.72% p.a.
Profit Margin
5.57%
Future PE
21.69x
Price in 2029
US$44.09
US$38.17
6.4% undervalued intrinsic discount
Revenue
10.92% p.a.
Profit Margin
5.26%
Future PE
24.02x
Price in 2029
US$46.39
US$40
10.7% undervalued intrinsic discount
Revenue
18.78% p.a.
Profit Margin
4.48%
Future PE
28.41x
Price in 2028
US$48.4

Trending Discussion

Updated Narratives

PNTG logo

PNTG: AMED Asset Integration Will Drive Future Earnings Realization Potential

Fair Value: US$36 0.8% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
PNTG logo

PNTG: AMED Assets Are Expected To Underpin Future Upside Despite 2026 Guidance

Fair Value: US$38.17 6.4% undervalued intrinsic discount
6 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
PNTG logo

Aging Population And Home Care Will Expand Market Access

Fair Value: US$40 10.7% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Moderate growth potential with acceptable track record.

1 Risk
3 Rewards

The Pennant Group, Inc. Key Details

US$1.0b

Revenue

US$822.3m

Cost of Revenue

US$200.9m

Gross Profit

US$170.6m

Other Expenses

US$30.3m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
0.87
19.64%
2.96%
43.6%
View Full Analysis

About PNTG

Founded
2019
Employees
9700
CEO
Brent Guerisoli
WebsiteView website
pennantgroup.com

The Pennant Group, Inc. provides healthcare services in the United States. It operates in two segments, Home Health and Hospice Services, and Senior Living Services. The company offers home health services, including clinical services, such as nursing, speech, occupational and physical therapy, medical social work, and home health aide services; and hospice services comprising clinical care, education, and counseling services for the physical, spiritual, and psychosocial needs of terminally ill patients and their families. It also provides senior living services, such as residential accommodations, activities, meals, housekeeping, and assistance in the activities of daily living to seniors who are independent or who require some support. The company operates home health, hospice, and home care agencies, as well as senior living communities in Alabama, Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Tennessee, Texas, Utah, Washington, Wisconsin, and Wyoming. The Company was incorporated in 2019 and is headquartered in Eagle, Idaho.

Recent PNTG News & Updates

Narrative Update May 06

PNTG: AMED Asset Integration Will Drive Future Earnings Realization Potential

Analysts have raised Pennant Group's fair value estimate by $2 to $36, reflecting updated Street price targets and ongoing confidence that the company can gradually realize earnings potential from the AMED assets over time. Analyst Commentary Recent Street research has centered on how quickly Pennant Group can translate the AMED assets into consistent earnings and whether current valuation fairly reflects that path.

Recent updates

No updates